title: The role of IgA and IgA Fc receptors as anti-inflammatory agents.
abstract: METHODS
  Serum monomeric immunoglobulin A (IgA) has powerful immunomodulatory roles in its ability to suppress immune responses. Monomeric IgA acts through FcalphaRI, which plays a significant role in vivo in maintaining the integrity of immune responses by an inhibitory immunoreceptor tyrosine-based activation motif-mediated process and powerful inhibitory cellular effector mechanisms elicited by the IgA system.
  
  
  RESULTS
  Triggering of FcalphaRI-mediated inhibitory function by Fab anti-FcalphaRI-mediated inhibitory function is able to inhibit several inflammatory and autoimmune diseases including asthma and glomerulonephritis.
  
  
  CONCLUSIONS
  The use of monomeric IgA as a therapeutic tool in human inflammatory diseases may offer much potential.
authors.affiliation: Inserm U699, Paris, France. renato.monteiro@inserm.fr
authors.forename: Renato C
authors.initials: RC
authors.lastname: Monteiro
mesh_terms: D020816:Amino Acid Motifs; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use*; D015703:Antigens, CD / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D007070:Immunoglobulin A / Q000276:immunology* / Q000494:pharmacology / Q000627:therapeutic use; D007249:Inflammation / Q000276:immunology / Q000628:therapy; D051379:Mice; D018448:Models, Immunological; D010766:Phosphorylation / Q000276:immunology; D011499:Protein Processing, Post-Translational / Q000276:immunology; D053824:Protein Tyrosine Phosphatase, Non-Receptor Type 6 / Q000502:physiology; D051076:Proto-Oncogene Proteins c-fyn / Q000502:physiology; D011961:Receptors, Fc / Q000276:immunology / Q000627:therapeutic use*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D015703:Antigens, CD; C036832:Fc(alpha) receptor; D007070:Immunoglobulin A; D011961:Receptors, Fc; D051076:Proto-Oncogene Proteins c-fyn; D053824:Protein Tyrosine Phosphatase, Non-Receptor Type 6
references.citation: Clin Exp Immunol. 2005 Jun;140(3):478-90
references.pmid: 15932509
references.citation: J Pathol. 2006 Jan;208(2):270-82
references.pmid: 16362985
references.citation: Immunol Rev. 2009 Nov;232(1):59-71
references.pmid: 19909356
references.citation: J Clin Invest. 1975 Feb;55(2):368-76
references.pmid: 1127105
references.citation: Trends Immunol. 2003 Feb;24(2):55-8
references.pmid: 12547499
references.citation: Immunity. 2005 Jan;22(1):31-42
references.pmid: 15664157
references.citation: J Mol Biol. 1999 Mar 12;286(5):1421-47
references.pmid: 10064707
references.citation: Kidney Int. 1998 May;53(5):1321-35
references.pmid: 9573548
references.citation: J Biol Chem. 1999 Mar 12;274(11):7216-25
references.pmid: 10066783
references.citation: Annu Rev Immunol. 2008;26:513-33
references.pmid: 18370923
references.citation: Blood. 1994 Mar 1;83(5):1278-88
references.pmid: 8118031
references.citation: Immunol Rev. 2002 Dec;190:123-36
references.pmid: 12493010
references.citation: J Leukoc Biol. 1995 Jun;57(6):875-82
references.pmid: 7790770
references.citation: J Clin Immunol. 2008 May;28 Suppl 1:S56-61
references.pmid: 18202833
references.citation: Clin Exp Immunol. 1996 Sep;105(3):537-43
references.pmid: 8809146
references.citation: Clin Exp Immunol. 1978 Dec;34(3):423-8
references.pmid: 369752
references.citation: Cell Immunol. 1978 Mar 15;36(2):363-76
references.pmid: 343924
references.citation: Annu Rev Immunol. 2003;21:177-204
references.pmid: 12524384
references.citation: J Immunol. 2008 Feb 15;180(4):2669-78
references.pmid: 18250479
references.citation: Biochem J. 1990 Oct 15;271(2):285-96
references.pmid: 2241915
references.citation: J Exp Med. 1976 Nov 2;144(5):1227-42
references.pmid: 825608
references.citation: J Immunol. 2001 Feb 1;166(3):1781-9
references.pmid: 11160224
references.citation: J Leukoc Biol. 1998 May;63(5):636-42
references.pmid: 9581809
references.citation: Nature. 2003 Jun 5;423(6940):614-20
references.pmid: 12768205